abstract |
The invention provides antibody conjugates comprising an antibody binding domain specific for CD3, a folate receptor ligand capable of binding to a folate receptor and a photocleavable moiety which inhibits binding of the antibody binding domain to CD3. The antibody conjugates may be used in methods of treating cancer, wherein one or more of the cells of the cancer express folate receptor. The invention also provides a method of killing a cancer cell by contacting the cancer cell with an antibody conjugate of the invention, irradiating the conjugate to cleave the photocleavable moiety from the conjugate and contacting the cancer cell with a T cell. |